for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Qiagen NV

QIA.DE

Latest Trade

39.55EUR

Change

-0.45(-1.13%)

Volume

255,135

Today's Range

39.52

 - 

40.33

52 Week Range

22.54

 - 

42.98

As of on the XETRA ∙ Minimum 15 minute delay

Latest Developments

Qiagen Reports Full Results For Second Quarter And First Half Of 2020

Aug 4 (Reuters) - QIAGEN NV <QIA.DE>::QIAGEN REPORTS FULL RESULTS FOR SECOND QUARTER AND FIRST HALF OF 2020.Q2 NET SALES OF $443.3 MILLION (+16% ACTUAL, +19% CER).Q2 DILUTED EPS $0.38; ADJUSTED EPS $0.55 ($0.56 CER, +70% CER).QIAGEN BOARDS HAVE REAFFIRMED UNANIMOUS RECOMMENDATION THAT QIAGEN SHAREHOLDERS ACCEPT THERMO FISHER OFFER AND TENDER THEIR SHARES ON OR BEFORE AUGUST 10.

Qiagen Publishes Position Statement For Proposed Acquisition By Thermo Fisher

July 22 (Reuters) - QIAGEN NV <QIA.DE>::QIAGEN ANNOUNCES PUBLICATION OF SUPPLEMENTAL REASONED POSITION STATEMENT FOR PROPOSED ACQUISITION BY THERMO FISHER.QIAGEN NV - OFFER DOCUMENT RELATES TO RECOMMENDED OFFER BY THERMO FISHER TO FULLY ACQUIRE ALL ISSUED ORDINARY SHARES IN QIAGEN FOR AN INCREASED OFFER PRICE OF EUR 43.00 PER QIAGEN SHARE IN CASH, AS ANNOUNCED ON JULY 16, 2020..

Davidson Kempner Says It Is Increasingly Apparent That Fair Value Of Qiagen Is Well In Excess Of Current Stock Price

July 15 (Reuters) - Davidson Kempner says::SIGNIFICANT PROFIT UPGRADE CONFIRMS CONCERNS THAT QIAGEN IS SEVERELY UNDERVALUED BY CURRENT THERMO FISHER SCIENTIFIC OFFER.IT IS INCREASINGLY APPARENT THAT FAIR VALUE OF QIAGEN IS WELL IN EXCESS OF CURRENT STOCK PRICE.USING COMPANY'S OWN UPDATED NUMBERS OF $2/SHARE OF ADJUSTED EPS FOR 2020 RESULTS IN A VALUATION OF EUR 51.3/SHARE, ON $2.36/SHARE OF ADJUSTED EPS FOR 2021 RESULTS IN A VALUATION OF EUR 55.7/SHARE.

Qiagen Sees Net Sales Growth Of Around 15-18% In 2020

July 13 (Reuters) - Qiagen NV <QIA.DE>::DGAP-ADHOC: QIAGEN N.V.: QIAGEN PROVIDES OUTLOOK FOR THIRD QUARTER AND FULL-YEAR 2020 AS WELL AS EXPECTATIONS FOR 2021.QIAGEN N.V.: QIAGEN PROVIDES OUTLOOK FOR Q3 AND FULL-YEAR 2020 AS WELL AS EXPECTATIONS FOR 2021.ANNOUNCES ITS OUTLOOK FOR Q3 AND FULL-YEAR 2020 FOR NET SALES AND ADJUSTED EARNINGS PER SHARE AS WELL AS EXPECTATIONS FOR 2021.FOR Q3 OF 2020, QIAGEN EXPECTS NET SALES GROWTH OF APPROXIMATELY 16-21% AT CONSTANT EXCHANGE RATES (CER) COMPARED TO $383 MILLION IN SAME PERIOD OF 2019.ADJUSTED EARNINGS PER SHARE (EPS) TO GROW APPROXIMATELY 45-60% CER TO ABOUT $0.52-0.58 CER FROM $0.36 IN YEAR-AGO QUARTER.OUTLOOK IS BASED ON EXPECTATIONS FOR A CONTINUATION OF TRENDS FROM FIRST HALF OF 2020 INTO THIRD AND FOURTH QUARTERS OF YEAR.SUSTAINED ELEVATED DEMAND FOR CORONAVIRUS TEST PRODUCTS IS EXPECTED TO MORE THAN OFFSET WEAKER YEAR-OVER-YEAR SALES TRENDS IN OTHER AREAS OF PORTFOLIO.FOR FULL-YEAR 2020, QIAGEN EXPECTS NET SALES GROWTH OF APPROXIMATELY 15-18% CER FROM 2019 LEVEL OF $1.53 BILLION.SEES 2020 ADJUSTED EPS GROWTH OF AT LEAST 40% CER TO AT LEAST $2.00 CER FROM $1.43 PER SHARE IN 2019.QIAGEN CURRENTLY EXPECTS A CONTINUATION OF NET SALES GROWTH AT A DOUBLE-DIGIT CER PACE FOR 2021 COMPARED TO FULL-YEAR 2020 RESULTS, AND FOR ADJUSTED EPS GROWTH OF AT LEAST 18% CER FROM RESULTS IN 2020.

Qiagen Q2 Net Sales Rose About 18-19% Compared To Year Ago

July 9 (Reuters) - QIAGEN NV <QIA.DE>::Q2 NET SALES ROSE APPROXIMATELY 18-19% AT CONSTANT EXCHANGE RATES (CER) FROM $381.6 MILLION IN SAME PERIOD OF 2019.BETTER-THAN-EXPECTED NET SALES GROWTH REFLECTS VERY SIGNIFICANT DEMAND FOR SOLUTIONS USED IN COVID-19 PANDEMIC TESTING AGAINST WEAKER CUSTOMER DEMAND TRENDS IN OTHER PRODUCT AREAS.CONTINUES TO EXPERIENCE UNPRECEDENTED DEMAND FOR PRODUCTS USED IN CORONAVIRUS TESTING.EXPECTS CURRENCY MOVEMENTS AGAINST U.S. DOLLAR (REPORTING CURRENCY) TO HAVE AN ADVERSE IMPACT ON RESULTS FOR Q2 OF 2020 OF ABOUT 2-3 PERCENTAGE POINTS ON NET SALES AT ACTUAL RATES.

Qiagen Provides Information On Potential Capital Gain From Its Minority Investment In ArcherDX

June 23 (Reuters) - Qiagen NV <QIA.DE>::QIAGEN PROVIDES INFORMATION ON POTENTIAL CAPITAL GAIN FROM ITS MINORITY INVESTMENT IN ARCHERDX.QIAGEN NV - AS OF JUNE 23, HELD EQUITY STAKE ON FULLY DILUTED BASIS IN ARCHER DX OF ABOUT 8%.QIAGEN NV - ESTIMATES PRE-TAX CAPITAL GAIN FROM INVESTMENT IN ARCHERDX COULD BE ABOUT $120 MILLION.

Thermo Fisher Scientific Publishes Offer Document For Voluntary Tender Offer For All Ordinary Shares Of Qiagen N.V.

May 18 (Reuters) - Thermo Fisher Scientific <TMO.N>::THERMO FISHER SCIENTIFIC PUBLISHES OFFER DOCUMENT FOR VOLUNTARY TENDER OFFER FOR ALL ORDINARY SHARES OF QIAGEN N.V..THERMO FISHER SCIENTIFIC INC - TRANSACTION EXPECTED TO CLOSE IN FIRST HALF OF 2021.THERMO FISHER SCIENTIFIC INC - ACCEPTANCE PERIOD FOR CASH OFFER OF EUR 39 PER QIAGEN SHARE RUNS FROM MAY 18, 2020, TO JULY 27, 2020.

Qiagen To Hold Virtual AGM On June 30

May 18 (Reuters) - Qiagen NV <QIA.DE>::QIAGEN ANNOUNCES PUBLICATION OF REASONED POSITION STATEMENT FOR PROPOSED ACQUISITION BY THERMO FISHER AND DATE FOR ANNUAL GENERAL MEETING.QIAGEN ANNOUNCED THAT ANNUAL GENERAL MEETING OF SHAREHOLDERS (AGM) IS PLANNED TO BE HELD ON JUNE 30.AGM WILL ALSO COVER A NUMBER OF ITEMS RELATING TO RECOMMENDED TAKEOVER OFFER.SHAREHOLDERS WILL NOT BE GIVEN PHYSICAL ACCESS TO THIS YEAR'S AGM.

Thermo Fisher Publishes Voluntary Tender Offer For All Ordinary Shares Of Qiagen N.V.

May 18 (Reuters) - Thermo Fisher Scientific Inc <TMO.N>::THERMO FISHER SCIENTIFIC PUBLISHES OFFER DOCUMENT FOR VOLUNTARY TENDER OFFER FOR ALL ORDINARY SHARES OF QIAGEN N.V..VOLUNTARY TENDER OFFER FOR ALL OF ORDINARY SHARES OF QIAGEN AT AN OFFER PRICE OF EUR 39 PER SHARE IN CASH.ACCEPTANCE PERIOD FOR CASH OFFER OF EUR 39 PER QIAGEN SHARE RUNS FROM MAY 18, 2020, TO JULY 27, 2020.

Qiagen Q1 Net Sales Up At $372.1 Million

May 6 (Reuters) - QIAGEN NV <QIA.DE>::Q1 SALES ROSE 7 PERCENT TO 372.1 MILLION USD.Q1 NET SALES OF $372.1 MILLION (+7% ACTUAL, +9% CER VERSUS. ABOUT+2-3% CER OUTLOOK).Q1 DILUTED EPS $0.17; ADJUSTED EPS $0.34 ($0.34 CER VERSUS. ABOUT $0.28-0.29 CER OUTLOOK).Q1 NET SALES OF $372.1 MILLION, +7% ACTUAL.QTRLY DILUTED EPS $0.17.BASED ON TRENDS TO DATE, WE EXPECT ONGOING STRONG GROWTH FOR Q2 OF 2020 IN BOTH SALES AND ADJUSTED EARNINGS PER SHARE.PLANS FOR A 50-FOLD INCREASE IN OUR OUTPUT OF VIRAL RNA EXTRACTION KITS..

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up